NASDAQ:HRTX Heron Therapeutics (HRTX) Stock Price, News & Analysis $0.32 +0.00 (+1.21%) Closing price 04:00 PM EasternExtended Trading$0.32 0.00 (-0.57%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Heron Therapeutics Stock (NASDAQ:HRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Heron Therapeutics alerts:Sign Up Key Stats Today's Range$0.31▼$0.3250-Day Range$0.30▼$0.5152-Week Range$0.30▼$1.58Volume1.10 million shsAverage Volume1.79 million shsMarket Capitalization$60.33 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingHold Company Overview Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing medicines for acute care and oncology. The company uses its Biochronomer drug-delivery platform to formulate therapies intended to provide sustained drug release and improve treatment convenience, efficacy, or tolerability. Heron’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postsurgical pain. The company also markets APONVIE, an injectable formulation of aprepitant used to help prevent postoperative nausea and vomiting in adults. Heron has also developed and commercialized oncology-support products, including CINVANTI, an intravenous formulation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting, and SUSTOL, an extended-release formulation of granisetron. Founded in 2011 and headquartered in San Diego, California, Heron serves healthcare providers and patients primarily in the United States. Its business is centered on advancing and commercializing differentiated therapies for hospital, surgical, and oncology settings, with an emphasis on addressing unmet needs in supportive care.AI Generated. May Contain Errors. Read More Heron Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreHRTX MarketRank™: Heron Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 553rd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingHeron Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 3 hold ratings, and 1 sell rating.Upside PotentialHeron Therapeutics has a consensus price target of $2.00, representing about 529.3% upside from its current price of $0.32.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Heron Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($0.14) to ($0.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHeron Therapeutics has a P/B Ratio of 4.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Heron Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.17% of the float of Heron Therapeutics has been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 18.54, which indicates bearish sentiment.Change versus previous monthShort interest in Heron Therapeutics has recently decreased by 4.01%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.30 News SentimentHeron Therapeutics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Heron Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for HRTX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.10% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Heron Therapeutics' insider trading history. Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HRTX Stock News HeadlinesHeron (HRTX) Q2 2026 Earnings Call TranscriptAugust 17, 2026 | finance.yahoo.comHeron Therapeutics Extends Tax Benefit Preservation Plan TimelineAugust 14, 2026 | tipranks.com$747 million in one quarter - with a 60% cash-flow targetThe company posted $747 million in net income last quarter and plans to return at least 60% of 2026 free cash flow to shareholders. Institutions control roughly 88% of shares, with BlackRock and Vanguard among the largest holders. A multi-year Palantir partnership is driving toward $500 million in run-rate savings by year-end 2026. Last quarter alone, the company returned $189 million to shareholders and repurchased 2.8 million shares.September 16 at 1:00 AM | Monument Traders Alliance (Ad)Heron outlines covenants through 2027 and pro forma cash of $24.3M after September debt paymentAugust 11, 2026 | seekingalpha.comHeron Therapeutics Announces Second Quarter 2026 Financial ResultsAugust 11, 2026 | markets.businessinsider.comHeron Therapeutics withdraws 2026 guidance as CINVANTI patent risk and strategic review cloud outlookAugust 11, 2026 | msn.comHeron Therapeutics to Report Second Quarter 2026 Financial Results on August 10 July 27, 2026 | quiverquant.comQHeron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026July 27, 2026 | globenewswire.comSee More Headlines HRTX Stock Analysis - Frequently Asked Questions How have HRTX shares performed this year? Heron Therapeutics' stock was trading at $1.30 on January 1st, 2026. Since then, HRTX stock has decreased by 75.6% and is now trading at $0.3178. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) issued its earnings results on Monday, August, 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by $0.03. The biotechnology company had revenue of $37.67 million for the quarter, compared to analysts' expectations of $42.19 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 293.02% and a negative net margin of 22.52%. Read the conference call transcript. Does Heron Therapeutics have any subsidiaries? Heron Therapeutics subsidiaries include these companies: Heron Therapeutics B.V.. Who are Heron Therapeutics' major shareholders? Heron Therapeutics' top institutional shareholders include BlackRock Inc. (5.57%), Tejara Capital Ltd (3.44%), Pale Fire Capital SE (1.32%) and GSA Capital Partners LLP (0.55%). Insiders that own company stock include Rubric Capital Management Lp, Adam Morgan, Craig A Collard, Ira Duarte and William P Forbes. View institutional ownership trends. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings8/10/2026Today9/16/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 HRTX's financial health is in the Red zone, according to TradeSmith. HRTX has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HRTX CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees128Year Founded1983Price Target and Rating Average Price Target for Heron Therapeutics$2.00 High Price Target$2.00 Low Price Target$2.00 Potential Upside/Downside+529.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.19 million Net Margins-22.52% Pretax Margin-22.52% Return on Equity-293.02% Return on Assets-10.00% Debt Debt-to-Equity Ratio24.35 Current Ratio2.49 Quick Ratio1.51 Sales & Book Value Annual Sales$154.90 million Price / Sales0.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.07 per share Price / Book4.54Miscellaneous Outstanding Shares189,850,000Free Float178,271,000Market Cap$60.33 million OptionableOptionable Beta1.61 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:HRTX) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our PartnersYour backdoor link (still works)Bill Poulos is offering a private link to download his book Simple Options Trading For Beginners, bypassing th...Profits Run | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredElon’s “nude” scandal – a big opportunity? — Act before September 29A new AI mega computer is under construction in Tennessee, backed by Amazon, Nvidia and the U.S. government. ...InvestorPlace | SponsoredIran War SHOCK: My Source Told Me to Watch for ThisA Middle Eastern government just asked Trump for military help against Iran-backed forces. One analyst says...Banyan Hill Publishing | SponsoredBlackRock, Vanguard... and a 2.8 million-share buybackManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
